Skip to main content
2024 AAPD Annual Meeting Main banner
Itinerary Planner Sponsored by Cheng Crowns
Information & Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticket Required
Ticket Required
Sold Out
Sold Out
Recorded Session
Recorded Session
Back
Rate ePoster
View ePoster

Pulp Therapy

346 - Retrospective Examination of Clinical Outcomes in Primary Pulp Therapy

Friday, May 24, 2024
4:00 PM – 4:10 PM EST
Location: Exhibit Hall (back left corner of the hall, space 137)

    Presenting Author(s)

  • Junho Lee, DMD

    Resident
    University of Minnesota, Minneapolis, MN
    University of Minnesota
    MINNEAPOLIS, Minnesota, United States

    • Co-Author(s)

  • RJ

    Robert Jones, DDS PhD

    University of Minnesota

    • Research Mentor(s)

  • Robert S. Jones, DDS, PhD

    Associate Professor
    University of Minnesota
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Program Director(s)

  • Jeffrey Karp, D.M.D., M.S.

    Residency Program Director
    University of Minnesota, Minneapolis, MN
    School of Dentistry , University of Minnesota
    Minneapolis, Minnesota, United States

Abstract:

Retrospective Examination of Clinical Outcomes in Primary Pulp Therapy

Lee J, Jones RS (University of Minnesota, Minneapolis, MN)




Purpose: The purpose of this retrospective study was to investigate the clinical outcome of primary pulp therapy using ferric sulfate (FS) or a nasal spray containing oxymetazoline (NS-OXY) as the hemostatic agent.




Method: In this study, pulpotomies for primary molars (CDT code D3220), conducted at the University of Minnesota Pediatric Dental Clinic between 2018 and 2022, were systematically reviewed. The investigation included 166 cases incorporated for data analysis and used clinical failure as the primary outcome. The Restricted Mean Survival Time (RMST) to 30 months was utilized to compare survival curves between FS and NS-OXY medications.


Result: There was no statistical significant difference in the age between the hemostatic agents(W = 0.281, P=.597, F = 1.546, P=.215). The RMST up to 30 months was 28.29 months for cases treated with FS (SE: 0.47, 95% CI: [27.37-29.21]) and 27.48 months (SE: 1.24, 95% CI: [25.02-29.87]) for cases treated with NS-OXY P=.52).  No specific mediators were identified.




Conclusion: This also showed similar and high RMST between ferric sulfate and NS-OXY that were used as hemostatic agents in primary pulpotomies. 

Identify Supporting Agency and Grant Number: